Non-Small-Cell Lung Cancers with High and Low Risk of Distant Metastasis Demonstrate Distinct Mutational Landscapes
Cancers · 12.11.2026 · 18 (22) · 3622
DOI: 10.3390/cancers18223622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 12.11.2026. Verfasst von Anastasia A. Korobeynikova und 16 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Education and Science of the Russian Federation.
Abstract (Originalsprache)
Background
Preventing metastasis is important for improving the survival rates of patients with non-small-cell lung cancer (NSCLC). Our previous investigation suggested that premalignant epithelial changes in small bronchi distant from the primary tumor serve as predictive markers of NSCLC metastasis. Specifically, isolated basal cell hyperplasia (iBCH) is associated with a high risk of distant metastasis, whereas basal cell hyperplasia combined with squamous metaplasia (BCH + SM) correlates with a low risk of distant metastasis.
Methods
This exploratory study included patients enrolled both retrospectively and prospectively. A total of 83 NSCLC patients were stratified into two groups: iBCH (high metastatic risk, n = 59, including 37 metastatic events) and BCH + SM (low metastatic risk, n = 24, including 6 metastatic events). Paired peripheral blood and tumor samples from NSCLC patients with iBCH and BCH + SM were subjected to whole exome sequencing. Bioinformatic analysis included tumor mutation quantification, detection of regions with enriched mutations, mutational signatures profiling, and evaluation of metastasis-free survival and hazard ratio modeling.
Results
Patients with iBCH were characterized by a higher prevalence of single nucleotide variants and a lower frequency of frameshift mutations. Single-nucleotide indels (mainly insertions) were more frequent in patients with BCH + SM. Additionally, ID1, ID3, ID11, and ID13 mutational signatures were significantly enriched in patients with BCH + SM. Moreover, the combination of SBS3, SBS4, DBS1, DBS2, DBS6, ID8, and ID23 signatures was linked to distant metastasis in NSCLC patients. Finally, a multivariable logistic regression model for assessing the probability of distant metastasis in NSCLC was developed based on the histological subtype, the bronchial lesion, and mutational signature.
Conclusions
NSCLC with high and low risk of distant metastasis defined by bronchial lesions have specific mutational landscapes.
Förderung
- the Ministry of Education and Science of the Russian Federation
Zitieren
APA
Korobeynikova, A. A., Aksenova, A. Y., Zhuk, A. S., Gerashchenko, T. S., Vorobiev, R. S., Tretyakova, M. S., Khozyainova, A. A., Rodionov, E. O., Zavyalova, M. V., Loos, D. M., Miller, S. V., Topolnitsky, E. B., Shefer, N. A., Zhuikova, L. D., Pankova, O. V., Perelmuter, V. M., & Denisov, E. V. (2026). Non-Small-Cell Lung Cancers with High and Low Risk of Distant Metastasis Demonstrate Distinct Mutational Landscapes. Cancers, 18(22), 3622. https://doi.org/10.3390/cancers18223622
Vancouver
Korobeynikova AA, Aksenova AY, Zhuk AS, Gerashchenko TS, Vorobiev RS, Tretyakova MS, et al. Non-Small-Cell Lung Cancers with High and Low Risk of Distant Metastasis Demonstrate Distinct Mutational Landscapes. Cancers. 2026;18(22):3622. doi:10.3390/cancers18223622
BibTeX
@article{Korobeynikova2026,
author = {Korobeynikova, Anastasia A. and Aksenova, Anna Y. and Zhuk, Anna S. and Gerashchenko, Tatiana S. and Vorobiev, Rostislav S. and Tretyakova, Maria S. and Khozyainova, Anna A. and Rodionov, Evgeny O. and Zavyalova, Marina V. and Loos, Dmitry M. and Miller, Sergey V. and Topolnitsky, Evgeniy B. and Shefer, Nikolay A. and Zhuikova, Lilia D. and Pankova, Olga V. and Perelmuter, Vladimir M. and Denisov, Evgeny V.},
title = {Non-Small-Cell Lung Cancers with High and Low Risk of Distant Metastasis Demonstrate Distinct Mutational Landscapes},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3622},
doi = {10.3390/cancers18223622}
}
EUVIMED